Brief: Acorda Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results
Acorda Therapeutics Inc ACOR.O :
* ACORDA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2021
FINANCIAL RESULTS
* Q4 NON-GAAP LOSS PER SHARE $0.67
* Q4 GAAP LOSS PER SHARE $1.73
* SEES FY REVENUE $68 MILLION TO $78 MILLION
* Q4 REVENUE $22.5 MILLION VERSUS $25.3 MILLION
Source text for Eikon: ID:nBw1sRvTTa
Further company coverage: ACOR.O
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease